Cefoperazone + sulbactam

Hypersensitivity to cefoperazone, sulbactam, or other β-lactam antibacterials (e.g. cephalosporin, penicillin).

Patient with severe biliary obstruction, poor diet, malabsorption states (e.g. cystic fibrosis). Patient on prolonged IV alimentation regimens or receiving anticoagulant therapy. Renal and severe hepatic impairment. Pregnancy and Lactation. Monitoring Parameters Monitor haematologic status (e.g. prothrombin time), renal, and hepatic function as clinically indicated. Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks.

Significant: Vitamin K deficiency resulting to coagulopathy, overgrowth of nonsusceptible organisms (prolonged use). Blood and lymphatic system disorders: Neutropenia, leucopenia, eosinophilia, thrombocytopenia, hypoprothrombinaemia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea. General disorders and administration site conditions: Pyrexia, chills, infusion site phlebitis, injection site pain. Hepatobiliary disorders: Jaundice. Investigations: Decreased haemoglobin, haematocrit; increased AST, ALT, blood alkaline phosphatase, blood bilirubin. Nervous system disorders: Headache. Renal and urinary disorders: Haematuria. Skin and subcutaneous tissue disorders: Pruritus, urticaria, maculopapular rash. Vascular disorders: Hypotension, vasculitis.
Potentially Fatal: Clostridium difficile-associated diarrhoea, hypersensitivity reactions including anaphylactoid and severe cutaneous adverse reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome, dermatitis exfoliative); serious haemorrhage.

May increase INR with anticoagulants (e.g. warfarin) thereby potentiating the risk for bleeding.

Cephalosporins

J01DD12 - cefoperazone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
J01CG01 - sulbactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.